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Functional, stem-cell-containing cardiac grafts will require vascularized myocardial constructs to support
their survival and integration into the host vasculature. Recently in Tissue Engineering, Part A, Lesman
et al. (2009) reported the successful integration of vascular cells and hESC-derived cardiomyoctyes into
stable grafts in rat recipients.Heart failure remains the leading cause of
death in the world. As one of the least
regenerative organs in the body, the heart
wall is primarily composed of cardiomyo-
cytes (CMs) and fibroblasts that are tightly
packed with supporting vasculature
and collagen-rich extracellular matrix.
Following myocardial infarction, an enor-
mous number of dead CMs are replaced
by thick, stiff fibrous scars, resulting in
the heart’s reduced contractile function
and, ultimately, heart failure. Clearly,
understanding how such a complex organ
develops from various different progeni-
tors in the body will help us to unlock
the full potential of stem cell biology
for cardiovascular therapy (reviewed in
Hansson et al., 2009). Cardiac tissue engi-
neering endeavors to generate functional
tissue constructs that can reestablish
the structure and function of the injured
myocardium. Human embryonic stem
cells (hESCs) can generate bona fide
CMs, as well as the supporting vascular
cells. In an earlier study (Caspi et al.,
2007), the Gepstein laboratory showed
that, when CMs and endothelial cells
(ECs) derived from hESCs are cultured
with mouse embryonic fibroblasts
(MEFs) within a three-dimensional scaf-
fold, they recapitulate early embryonic
heart development. Now, in their current
work, the same group demonstrates that
tissue-engineered vascularized cardiac
muscle, generated ex vivo, can form
stable grafts in vivo (Lesman et al., 2009).
Implantation of thick, complex con-
structs has always been a challenge in
tissue engineering. Once implanted, the
engineered cardiac grafts must endure
a hostile ischemic microenvironment with
a minimal diffused oxygen supply andhigh metabolic demand. Consequently,
significant cell death follows transplanta-
tion, even in the absence of an injury
model, mainly due to insufficient graft
vascularization. The degree of graft
vascularization is crucial not only for the
survival and integration of the engineered
cardiac grafts, but also for their proper
contractile function. Prevascularization
of cardiac grafts can be done either
in vivo or in vitro. Recently, the Cohen
laboratory designed a strategy for the
in vivo prevascularization of cardiac grafts
by heterotypic transplantation onto the
omentum (Dvir et al., 2009). A porous algi-
nate scaffold was seeded with neonatal
CMs in a mixture of Matrigel with prosur-
vival and angiogenic factors; once tissue
organization was achieved, the engi-
neered cardiac graft was transplanted
onto the omentum, a blood-vessel-en-
riched membrane, for further maturation
and vascularization. A sustained release
of angiogenic factors was able to attract
ECs and other perivascular cells, resulting
inahighly vascularizedengineeredcardiac
graft. This graft was then explanted and
transplanted onto an infarcted heart,
demonstrating structural and electrical
integration into the host myocardium.
An alternative strategy involves prevas-
cularizing the engineered construct
in vitro by providing vascular cells and
angiogenic factors. Previously, the Langer
laboratory demonstrated an approach for
the in vitro prevascularization of skeletal
tissue constructs (Levenberg et al., 2005).
In vitro prevascularization was found to
require the triculture of myoblasts, ECs,
and fibroblasts to generate stable vascu-
larization within the engineered skeletal
muscle constructs. In their recent report,Cell Stem Cell 5,the Gepstein laboratory describes a well-
designed and well-controlled study to
engineer a vascularized cardiac muscle
in vitro. Engineered cardiac tissue con-
structs were generated by culturing
hESC-derived CMs, human umbilical vein
endothelial cells, and MEFs in synthetic
biodegradable scaffolds coated with Ma-
trigel (Figure 1). After 2 weeks in culture,
the engineered constructs were fully vas-
cularized and exhibited synchronized
beating. Upon grafting onto rat hearts,
these triculture cardiac constructs ex-
hibited a superior and more complex
vascularization than transplanted scaf-
folds containing only hESC-derived CMs.
Additionally, more CD31+ and a-SMA+
cells were found in the triculture
constructs, suggesting their integration
with the host vasculature. These exciting
findings support the hypothesis that
perivascular cell precursors, such as
embryonic fibroblasts, can serve as active
partners with ECs in forming stable and
functional blood vessels (Hirschi et al.,
1998). The research suggested three vital
roles played by embryonic fibroblasts in
the formationof stable blood vessels. First,
this population was spread diffusely
throughout the cardiac graft, suggesting
their role in layingdownextracellularmatrix
to direct vascular morphogenesis. Sec-
ond, MEF-derived cells were foundmostly
near the vessel wall and were positive for
a-SMA, suggesting that they differentiated
into vascular smooth muscle cells to
provide physical integrity to the vessels.
Third, the triculture systems were found
to highly express vascular endothelial
growth factor, platelet-derived growth
factor BB, and angiopoietin-1—all angio-
genic factors necessary for the survival ofDecember 4, 2009 ª2009 Elsevier Inc. 575
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findings highlight the impor-
tance of combining different
cell types to capitalize on their
synergistic roles in engi-
neering functional tissue
constructs.
Once the prevascularized
cardiac constructs can anas-
tomosewith the host vascula-
ture, the next challenge is to
promote CM maturation and
synchronization with the elec-
trical syncytium of the exist-
ing myocardium, rather than
maintaining their own sponta-
neous contractile activity.
Indeed, upon engraftment,
the prevascularized cardiac
constructs were able to
induce CM maturation into
elongated andmultinucleated
myotubes, which contained
gap junctions and were orga-
nized anisotropically (Lesman
et al., 2009). Interestingly, the
degree of CM maturation
varied among rats, raising
the question of whether the
degree of graft vasculariza-
tion affects CM maturation.
Early and late markers of
CM differentiation and maturation were
highly upregulated in the triculture system
but not observed in scaffolds containing
only hESC-derived CMs (Lesman et al.,
2009). These findings add to the growing
body of evidence linking vascularization
and tissue differentiation (Jain, 2003),
which is crucial when bioengineering
a complex and highly vascularized organ.
Yet, a critical issue remains: the functional
status of the engineered cardiac grafts.
Because the hallmark of a functional adult
heart is its ability to propagate intricate
electrical impulses and to beat synchro-
nously, a relatively immature CM must
be further developed, for example by
electromechanical stimulation (Vunjak-
Novakovic et al., 2009), and tested
in vitro prior to transplantation (Song
et al., 2009). It would be interesting to
investigate how the degrees of CM
maturation, vascularization, and tissue
perfusion affect the electrophysiological
function of the engrafted heart.
As the emerging field of cardiovascular
engineering moves closer to clinical appli-
cation, this elegant work from the Gep-
stein laboratory raises several new ques-
tions for investigation. Recent exciting
findings on induced pluripotent stem cells
(iPSCs) open the possibility of creating
patient-specific therapies for cardiac
regeneration. However, engineering an
autologous cardiac graft from iPSCs
without genetic transformation remains
to be addressed. Another critical chal-
lenge is to engineer a fully defined
construct that can be transplanted into
a patient without any animal byproducts.
As a proof of concept, most cardiac grafts
to date have used Matrigel or
other animal-derivedmatrices
to facilitate cell adhesion and
vascularization. The challenge
remains to develop a xeno-
free matrix that mimics the
in vivo microenvironments,
directs CM differentiation,
induces vascularization, and
supports tissue organization.
Combining the best of both
worlds—stem cell biology
and tissue engineering—the
next era of cardiac regenera-
tion could be closer than ever.
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Figure 1. Engineering Cardiac Tissue Constructs
hESC-derived cardiomyocytes (CMs), human umbilical vein endothelial cells
(HUVECs), andmouse embryonic fibroblasts (MEFs) were cultured in synthetic
biodegradable scaffolds coated withMatrigel and transplanted into a rat heart.576 Cell Stem Cell 5, December 4, 2009 ª2009 Elsevier Inc.
